首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1544692

胃癌治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Stomach Cancer Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月12日 | 出版商:

Global Market Insights Inc. | 英文 281 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於研究和臨床試驗的加強，預計 2024 年至 2032 年胃癌治療市場的複合年成長率將達到 13.5%。

研究人員正在研究新的療法和治療方法，以改善胃癌患者的預後。臨床試驗處於最前沿，評估突破性藥物、標靶治療和個人化醫療策略，所有這些都旨在增強療效，同時最大限度地減少副作用。這些試驗也探索創新的治療組合和先進的方法，以製定更有效和客製化的治療方案。例如，2023年11月，美國FDA擴大了Pembrolizumab的適用範圍，批准其用於胃癌和食道交界癌，從而為這些患者引入了新的治療途徑。

整個市場分為類型、適應症、藥物類別、給藥途徑、配銷通路和地區。

就類型而言，到 2032 年，由於增強人體對癌細胞的免疫反應的迫切需要，胃癌治療市場的免疫治療領域將經歷強勁成長。研究人員正在積極開發和評估從檢查點抑制劑到 CAR-T 細胞療法的多種免疫治療方式，所有這些都是為了提高治療效果。免疫療法的機制圍繞著精確定位癌細胞中的特定蛋白質或調整免疫細胞以獲得更強大的腫瘤攻擊。此外，正在進行的研究正在深入研究聯合療法和客製化策略，以最大限度地提高療效，同時減少副作用。

按配銷通路，專業藥房和零售藥房領域的胃癌治療行業價值預計將在 2024 年至 2032 年期間上升。這些藥房不僅配發專門的藥物，例如標靶藥物和免疫療法，還提供個人化的患者諮詢。此外，專業藥局在管理複雜的治療方面發揮關鍵作用，確保患者接受藥物治療，同時提供必要的監測和依從性支持。

從地區來看，在醫療保健投資不斷增加的推動下，亞太地區胃癌治療市場規模預計將在 2024 年至 2032 年間實現強勁成長。這些投資不僅支持研發，還為突破性療法鋪平道路，包括標靶治療和免疫療法。此外，這些財政刺激正在促進臨床試驗的擴大，並增加患者獲得最先進治療的機會。作為這些努力的結晶，該地區預計將有更完善的治療方法、改善的患者治療效果以及更廣泛的有效治療方法。

產業生態系統分析
產業影響力
- 成長動力
  - 胃癌盛行率增加
  - 診斷技術的進步
  - 標靶治療的開發
  - 提高認知和篩檢計劃
- 產業陷阱與挑戰
  - 治療費用高
  - 與癌症治療相關的副作用和安全性問題
成長潛力分析
監管環境
技術景觀
- 核心技術
- 鄰近技術
2023 年定價分析
- 按地區
- 按關鍵人物
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
化療
免疫治療
標靶治療

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
胃癌/胃食道結合部癌
胃腸道間質瘤

第 7 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
PD-1/PD-L1抑制劑
HER2拮抗劑
VEGFR2拮抗劑
其他藥物類別

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
可注射

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
專業藥局和零售藥局
其他分銷管道

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

AstraZeneca PLC
Bristol Myers Squibb Company
Bayer AG
Biocon Limited
Celltrion Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Ipsen Pharma
Merck and Co., Inc.
Novartis AG
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

簡介目錄

Product Code: 10227

Stomach Cancer Treatment Market is projected to record a 13.5% CAGR from 2024 to 2032, driven by an intensified emphasis on research and clinical trials.

Researchers are delving into novel therapies and treatment methodologies to bolster outcomes for stomach cancer patients. Clinical trials are at the forefront, evaluating groundbreaking drugs, targeted therapies, and personalized medicine strategies, all aimed at amplifying efficacy while minimizing side effects. These trials are also probing into innovative therapy combinations and advanced methodologies to curate more effective and customized treatment regimens. For example, in November 2023, the U.S. FDA broadened the scope of Pembrolizumab, approving it for stomach and esophageal junction cancer, thereby introducing a fresh therapeutic avenue for these patients.

The overall market is segregated into type, indication, drug class, route of administration, distribution channel, and region.

In terms of type, the immunotherapy segment in the stomach cancer treatment market will experience robust growth by 2032 led by the escalating imperative to bolster the body's immune response against cancer cells. Researchers are actively developing and evaluating diverse immunotherapy modalities, from checkpoint inhibitors to CAR-T cell therapy, all to enhance treatment outcomes. The mechanism of immunotherapy revolves around pinpointing specific proteins in cancer cells or tweaking immune cells for a more robust tumor attack. Furthermore, ongoing investigations are delving into combination therapies and tailored strategies to maximize efficacy while curtailing side effects.

By distribution channel, the stomach cancer treatment industry value from the specialty and retail pharmacies segment is projected to rise from 2024 to 2032. This surge is attributed to the increasing demand for a comprehensive range of therapies and ancillary support services. These pharmacies are not only dispensing specialized medications, such as targeted and immunotherapies but are also providing personalized patient counseling. Moreover, specialty pharmacies play a pivotal role in managing intricate treatments, ensuring patients receive their medications whilst offering essential monitoring and adherence support.

Regionally, the Asia Pacific stomach cancer treatment market size is projected to accrue robust growth between 2024 and 2032, fueled by rising healthcare investments. These investments are not just bolstering R and D but are also paving the way for groundbreaking therapies, including targeted treatments and immunotherapy. Furthermore, these financial boosts are facilitating the broadening of clinical trials and enhancing patient access to state-of-the-art treatments. As a culmination of these efforts, the region anticipates refined treatment methodologies, improved patient outcomes, and a wider reach of effective therapies.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of stomach cancer
  - 3.2.1.2 Advancements in diagnostic techniques
  - 3.2.1.3 Development of targeted therapies
  - 3.2.1.4 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Side effects and safety concerns associated with cancer therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Chemotherapy
5.3 Immunotherapy
5.4 Targeted therapy

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Gastric cancer /gastroesophageal junction cancer
6.3 Gastrointestinal stromal tumors

Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 PD-1/PD-L1 inhibitors
7.3 HER2 antagonists
7.4 VEGFR2 antagonists
7.5 Other drug classes

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Specialty and retail pharmacies
9.4 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa